Transcription Factor Design for AAV Packaging Limits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches using Adeno-associated virus (AAV) vectors are limited by their packaging capacity, making it difficult to deliver large therapeutic genes, and there is a need for small, strong transcription factors that can modulate gene expression with reduced immunogenicity and off-target effects.
Innovation Solution
Development of a transcription factor comprising a DNA binding domain and multiple transcriptional activation domains (TADs), such as acidic, Q-rich, and P-rich TADs, linked with a linker, to specifically target and enhance the expression of genes, using AAV vectors for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If AAV vectors are used to deliver therapeutic genes, then gene therapy can be achieved with reduced immunogenicity, but the packaging capacity limits delivery of large therapeutic genes
Solution Approach 1:
The patent extracts only the essential functional domains needed for gene activation (DNA binding domain and transcriptional activation domains) rather than delivering the entire therapeutic gene. This extraction approach reduces the genetic material size to fit within AAV packaging capacity while retaining the core therapeutic function of increasing gene expression.
Solution Approach 2:
The patent introduces a transcription factor as an intermediary molecule that binds to the promoter region of the target gene and activates transcription. This intermediary approach allows indirect gene therapy - instead of replacing the defective gene, a smaller transcription factor mediates the activation of endogenous gene expression, bypassing the packaging capacity limitation.
2Quantity of substance
If transcription factors are designed to be small for AAV delivery, then packaging capacity is satisfied, but transcriptional activation strength may be reduced
Solution Approach 1:
The patent combines multiple transcriptional activation domains (TADs) into a single transcription factor construct. By merging several TADs (such as VP16, VP64, p65, RTA domains) with a DNA binding domain, the design achieves both size constraints for AAV delivery and sufficient transcriptional activation strength through the cumulative effect of multiple activation domains working together.
Solution Approach 2:
The transcription factor is designed as a composite protein structure consisting of a DNA binding domain fused to multiple transcriptional activation domains. This composite design integrates different functional modules (specificity from DBD, activation strength from multiple TADs) into a single functional unit that satisfies both size and activity requirements for effective AAV-mediated gene therapy.
Data Source
AI summary
The present invention relates to novel transcription factors for modulating the expression of gene of interest, by fusing to a DNA binding domain that targets the gene of interest.